Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.

European journal of gastroenterology & hepatology - 1 Mar 2017

Tanwar Sudeep, Trembling Paul M, Hogan Brian J, Srivastava Ankur, Parkes Julie, Harris Scott, Grant Paul, Nastouli Eleni, Ocker Mathias, Wehr Klaus, Herold Christoph, Neureiter Daniel, Schuppan Detlef, Rosenberg William M

Abstract excerpt

AIM: The utility of noninvasive serum markers to longitudinally monitor liver fibrosis is not established. METHODS: A total of 70 patients with chronic hepatitis C who had previously failed antiviral therapy were randomized to receive pegylated interferon with or without silymarin for 24 months. Enhanced Liver Fibrosis (ELF) tests (hyularonic acid, terminal peptide of procollagen III, tissue inhibitor of matrix...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Austria

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyaluronic Acid

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Procollagen

Share to ROC Curve

Share to Tissue Inhibitor of Metalloproteinase-1

Source

Identifiers

PMID: 27906753
DOI: 10.1097/MEG.0000000000000789

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.PMID 27906753Read ↗

Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Semantic proximity Read ↗

How Effective Are Serum Scoring Systems in Predicting Liver Fibrosis Caused by Chronic Hepatitis B? Serum Scoring Systems and Liver FibrosisSemantic proximity Read ↗

Plasma TIMP-1 is a Useful Tool for Monitoring 24 Months Liver Fibrosis Improvement After Anti-HCV /DAA Therapy in HCV/HIV Mono/CoinfectionSemantic proximity Read ↗

Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.Semantic proximity Read ↗

Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.Semantic proximity Read ↗

Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality.Semantic proximity Read ↗

Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.Semantic proximity Read ↗

Pretreatment serum interferon gamma inducible protein-10 as biomarker of fibrosis and predictor of virological response in genotype 4 hepatitis C virus infection.Semantic proximity Read ↗

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.Semantic proximity Read ↗

Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.Semantic proximity Read ↗

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.Semantic proximity Read ↗

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.